Published Data
Published Data
Many of our clients have published their research and acknowledged TransPharm’s role in their work. Check out a few of the manuscripts and poster presentations based on studies we’ve completed.
S. aureus – 2013
Mechanism of Action and In Vivo Efficacy of a Human-Derived Antibody against Staphylococcus aureus α-Hemolysin
Pfizer
CLP Sepsis – 2013
Determination of the safety and efficacy of therapeutic neutralization of tumor necrosis factor-a (TNF-a) using AZD9773, an anti-TNF-a immune Fab, in murine CLP sepsis
AstraZeneca
P. acnes – 2016
Zolav®: A New Antibiotic for the Treatment of Acne
Boulos and Cooper Pharmaceuticals
P. aeruginosa – 2014
SASP: Efficacy of Pa SASPject against Pseudomonas aeruginosa ATCC 27853 in a Mouse Lung Model
Phico Therapeutics
C. difficile – 2015
Efficacy and Impact to the Microbiome of Novel Specifically-Targeted Antimicrobial Peptides against C. difficile Infection
C3J Therapeutics
C. difficile – 2017
Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile
Broad Institute of MIT and Harvard
C. albicans – 2016
Subcutaneous (SC) Injection of CD101, a Novel Echinocandin: Efficacious, Well-Tolerated, and Sustained Drug Exposures
Cidara Therapeutics
Staphylococcus enterotoxin B (SEB) – 2010
Generation and characterization of high affinity human monoclonal antibodies that neutralize staphylococcal enterotoxin B
Morphotek, Inc.